1H/19F Magnetic Resonance Molecular Imaging with Perfluorocarbon Nanoparticles

Current Topics in Developmental Biology

Volumn 70, Issue , 2005, Pages 57-76

  Lanza, Gregory M ^a   Winter, Patrick M ^a   Neubauer, Anne M ^a   Caruthers, Shelton D ^a,b   Hockett, Franklin D ^a   Wickline, Samuel A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; FLUOROCARBON; FREE RADICAL; NANOPARTICLE; PROTON;

ANIMAL; CHEMISTRY; HUMAN; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

ANIMALS; FLUORINE; FLUOROCARBONS; FREE RADICALS; HUMANS; MAGNETIC RESONANCE IMAGING; NANOPARTICLES; PROTONS;

EID: 33645937634     PISSN: 00702153     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0070-2153(05)70003-X     Document Type: Review

References (41)

1. 3-targeted nanoparticles. Magn. Reson. Med. 44 (2000) 433-439
2. Bulte J.W., Duncan I.D., and Frank J.A. In vivo magnetic resonance tracking of magnetically labeled cells after transplantation. J. Cereb. Blood Flow Metab. 22 (2002) 899-907
3. Daldrup-Link H.E., Rudelius M., Oostendorp R.A., Settles M., Piontek G., Metz S., Rosenbrock H., Keller U., Heinzmann U., Rummeny E.J., Schlegel J., and Link T.M. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 228 (2003) 760-767
4. Dardzinski B.J., and Sotak C.H. Rapid tissue oxygen tension mapping using 19F inversion-recovery echo-planar imaging of perfluoro-15-crown-5-ether. Magn. Reson. Med. 32 (1994) 88-97
5. Fan X., River J., Zamora M., Al-Hallaq H., and Karczmar G. Effect of carbogen on tumor oxygenation: Combined fluorine-19 and proton MRI measurements. Int. J. Radiat. Oncol. Biol. Phys. 54 (2002) 1202-1209
6. Flacke S., Fischer S., Scott M., Fuhrhop R., Allen J., Mc Lean M., Winter P., Sicard G., Gaffney P., Wickline S., and Lanza G. A novel MRI contrast agent for molecular imaging of fibrin:implications for detecting vulnerable plaques. Circulation 104 (2001) 1280-1285
7. Hahn P.F., and Saini S. Liver-specific MR imaging contrast agents. Radiol. Clin. North Am. 36 (1998) 287-297
8. Harisinghani M.G., Barentsz J., Hahn P.F., Deserno W.M., Tabatabaei S., van de Kaa C.H., de la Rosette J., and Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348 (2003) 2491-2499
9. Huang M., Ye Q., Williams D., and Ho C. MRI of lungs using partial liquid ventilation with water-in-perfluorocarbon emulsions. Magn. Reson. Med. 48 (2002) 487-492
10. Hunjan S., Zhao D., Canstandtinescu A., Hahan E., Antich P., and Mason R. Tumor oximetry: Demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging the Dunning prostate R3327-At1 rat tumor. Int. J. Radiat. Oncol. Biol. Phys. 49 (2001) 1097-1108
11. Ikehira H., Girard F., Obata T., Ito H., Yoshitomi H., Miyazaki M., Nakajiman N., Kamei H., Kanazawa Y., Takano H., Tanada S., and Sasaki Y. A preliminary study for clinical pharmacokinetics of oral fluorine anticancer medicines using the commercial MRI system 19F-MRS. Br. J. Radiol. 72 (1999) 584-589
12. Johansson L.O., Bjornerud A., Ahlstrom H.K., Ladd D.L., and Fujii D.K. A targeted contrast agent for magnetic resonance imaging of thrombus: Implications of spatial resolution. J. Magn. Reson. Imaging 13 (2001) 615-618
13. Kaufman C.L., Williams M., Ryle L.M., Smith T.L., Tanner M., and Ho C. Superparamagnetic iron oxide particles transactivator protein-fluorescein isothiocyanate particle labeling for in vivo magnetic resonance imaging detection of cell migration: Uptake and durability. Transplantation 76 (2003) 1043-1046
14. Kim J.Y., and Harisinghani M.G. MR imaging staging of pelvic lymph nodes. Magn. Reson. Imaging Clin. North Am. 12 (2004) 581-586
15. Kircher M.F., Mahmood U., King R.S., Weissleder R., and Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. 63 (2003) 8122-8125
16. Kohler G., and Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256 (1975) 495-497
17. Kooi M.E., Cappendijk V.C., Cleutjens K.B., Kessels A.G., Kitslaar P.J., Borgers M., Frederik P.M., Daemen M.J., and van Engelshoven J.M. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107 (2003) 2453-2458
18. Krafft M. Fluorocarbons and fluorinated amphiphiles in drug delivery and biomedical research. Adv. Drug Del. Rev. 47 (2001) 209-228
19. 111In-octreotide scintigraphy in oncology. Metabolism 41 (1992) 83-86
20. Lanza G., Lorenz C., Fischer S., Scott M., Cacheris W., Kaufman R., Gaffney P., and Wickline S. Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Acad. Radiol. 5 Suppl. 1 (1998) S173-S176
21. Lanza G., Wallace K., Scott M., Cacheris W., Abendschein D., Christy D., Sharkey A., Miller J., Gaffney P., and Wickline S. A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 94 (1996) 3334-3340
22. Lanza G.M., Yu X., Winter P.M., Abendschein D.R., Karukstis K.K., Scott M.J., Chinen L.K., Fuhrhop R.W., Scherrer D.E., and Wickline S.A. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: Implications for rational therapy of restenosis. Circulation 106 (2002) 2842-2847
23. Laukemper-Ostendorf S., Scholz A., Burger K., Heussel C., Schmittner M., Weiler N., Markstaller K., Eberle B., Kauczor H., Quintel M., Thelen M., and Schreiber W. 19F-MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation. Magn. Reson. Med. 47 (2002) 82-89
24. Moore A., Grimm J., Han B., and Santamaria P. Tracking the recruitment of diabetogenic CD8+ T-cells to the pancreas in real time. Diabetes 53 (2004) 1459-1466
25. Morawski A.M., Winter P.M., Crowder K.C., Caruthers S.D., Fuhrhop R.W., Scott M.J., Robertson J.D., Abendschein D.R., Lanza G.M., and Wickline S.A. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 51 (2004) 480-486
26. Morawski A.M., Winter P.M., Yu X., Fuhrhop R.W., Scott M.J., Hockett F., Robertson J.D., Gaffney P.J., Lanza G.M., and Wickline S.A. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 52 (2004) 1255-1262
27. Moulton K. Plaque angiogenesis and atherosclerosis. Curr. Atheroscler. Rep. 3 (2001) 225-233
28. Muhler A., Zhang X., Wang H., Lawaczeck R., and Weinmann H.J. Investigation of mechanisms influencing the accumulation of ultrasmall superparamagnetic iron oxide particles in lymph nodes. Invest. Radiol. 30 (1995) 98-103
29. Noth U., Grohn P., Jork A., Zimmermann U., Haase A., and Lutz J. 19F-MRI in vivo determination of the partial oxygen pressure in perfluorocarbon-loaded alginate capsules implanted into the peritoneal cavity and different tissues. Magn. Reson. Med. 42 (1999) 1039-1047
30. Ruehm S.G., Corot C., Vogt P., Cristina H., and Debatin J.F. Ultrasmall superparamagnetic iron oxide-enhanced MR imaging of atherosclerotic plaque in hyperlipidemic rabbits. Acad. Radiol. 9 Suppl. 1 (2002) S143-S144
31. Saini S., Edelman R.R., Sharma P., Li W., Mayo-Smith W., Slater G.J., Eisenberg P.J., and Hahn P.F. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: Initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227). AJR Am. J. Roentgenol. 164 (1995) 1147-1152
32. Schlemmer H., Becker M., Bachert P., Dietz A., Rudat V., Vanselow B., Wollensack P., Zuna I., Knopp M., Weidauer H., Wannenmacher M., and van Kaick G. Alterations of intratumoral pharacokinetics of 5-fluorouracil in head and neck carcinoma during simulataneous radiochemotherapy. Cancer Res. 59 (1999) 2363-2369
33. 3-targeted paramagnetic nanoparticles. Magn. Reson. Med. 53 (2005) 621-627
34. 3-targeted magnetic resonance imaging. Nat. Med. 4 (1998) 623-626
35. Sotak C.H., Hees P.S., Huang H.N., Hung M.H., Krespan C.G., and Raynolds S. A new perfluorocarbon for use in fluorine-19 magnetic resonance imaging and spectroscopy. Magn. Reson. Med. 29 (1993) 188-195
36. Vassallo P., Matei C., Heston W.D., McLachlan S.J., Koutcher J.A., and Castellino R.A. AMI-227-enhanced MR lymphography: Usefulness for differentiating reactive from tumor-bearing lymph nodes. Radiology 193 (1994) 501-506
37. Weissleder R., Elizondo G., Wittenberg J., Lee A.S., Josephson L., and Brady T.J. Ultrasmall superparamagnetic iron oxide: An intravenous contrast agent for assessing lymph nodes with MR imaging. Radiology 175 (1990) 494-498
38. Winter P., Caruthers S., Yu X., Song S., Fuhrhop R., Chen J., Miller B., Bulte J., Wickline S., and Lanza G. Improved molecular imaging contrast agent for detection of human thrombus. Magn. Reson. Med. 50 (2003) 411-416
39. 3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 63 (2003) 5838-5843
40. 3-integrin-targeted nanoparticles. Circulation 108 (2003) 2270-2274
41. Wolf W., Presant C., and Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 41 (2000) 55-74